|Mr. Cameron L. Groome||Pres, CEO & Director||517.44k||N/A||N/A|
|Mr. James S. Currie||Chief Financial Officer||253.56k||N/A||N/A|
|Dr. Kenneth Hughes Ph.D.||Chief Operating Officer||245.89k||N/A||N/A|
|Dr. Mark Luscher Ph.D.||Sr. VP of Scientific Affairs||209.26k||N/A||N/A|
|Mr. Philip Casselli||Sr. VP of Sales, Bus. Devel. & Marketing||233.3k||N/A||N/A|
|Mr. Christopher B. Lobb||Compliance Officer, Gen. Counsel & Sec.||N/A||N/A||N/A|
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Microbix Biosystems Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.